Catheter Precision, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
VTAK$0.15-0.7%Stored close · as of Oct 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(11,847) | $(11,015) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,588 | 1,578 |
| Stock-based compensation | 259 | 36 |
| Change in fair value of royalties payable due to related parties | 2,104 | 2,823 |
| Change in fair value of trading debt securities | (117) | — |
| Deferred income tax benefit | (1,596) | — |
| Acquired in-process research and development | 1,967 | — |
| Amortization of discount on note payable | 27 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (53) | 30 |
| Inventories | (21) | (7) |
| Prepaid expenses and other current assets | 62 | 108 |
| Operating lease right-of-use assets and lease liabilities | (5) | (1) |
| Current portion of royalties payable due to related parties | 7 | 17 |
| Accounts payable | 664 | 244 |
| Accrued expenses | 15 | (236) |
| Interest payable due to related parties | 138 | 16 |
| Interest accrued on notes payable of variable interest entities | 24 | — |
| Net cash used in operating activities | (6,784) | (6,407) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of acquired in-process research and development | (34) | — |
| Purchases of property and equipment | (17) | (67) |
| Net cash used in investing activities | (51) | (67) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of Series B Convertible Preferred Stock and other equity-classified warrants, net of issuance costs | 1,170 | — |
| Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs | — | 2,612 |
| Proceeds from issuance of common stock under ATM, net of issuance costs | 3,744 | — |
| Proceeds from notes payable due to related parties | 300 | 1,500 |
| Payments on notes payable | (177) | (184) |
| Proceeds from notes payable | — | 249 |
| Net cash provided by financing activities | 5,037 | 4,177 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (1,798) | (2,297) |
| CASH AND CASH EQUIVALENTS, beginning of period | 2,873 | 3,565 |
| CASH AND CASH EQUIVALENTS, end of period | $1,075 | $1,268 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $6 | $25 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Property and equipment reclassified from inventories | $20 | $19 |
| Note payable of variable interest entities issued in connection with an asset acquisition | $1,246 | $— |
| Fair value of common stock issued in connection with asset acquisitions | $393 | $— |
| Consideration for asset acquisition included in accounts payable | $185 | $— |
| Consideration for asset acquisition included in non-controlling interest | $109 | $— |
| Fair value of trading debt securities obtained as consideration for the Series B Convertible Preferred Stock and other equity-classified warrants | $864 | $— |
| Operating right-of-use asset obtained in exchange for new operating lease liabilities | $142 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.